New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...

MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

While discussing the use, safety and efficacy of GLP-1 drugs with Dr. Ania Jastreboff on the Jan. 14 episode of “The Oprah Podcast,” the Harpo Productions founder said her entire way of ...

Over 176 weeks, participants taking 15 mg of tirzepatide lost an average 22.9% of their body weight, compared with 19.9% with 10 mg, 15.4% with 5 mg, and 2.1% with placebo (P<0.001), reported Ania ...

M edia maven Oprah Winfrey stirred controversy during a recent “The Oprah Podcast” episode with Yale University obesity medicine physician Dr. Ania Jastreboff. The converoversial conversation ...